PolyPid Ltd
PYPD3.510USD
+0.110+3.24%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
35.77MCap. mercado
PérdidaP/E TTM
Más Datos de PolyPid Ltd Compañía
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Información de la empresa
Símbolo de cotizaciónPYPD
Nombre de la empresaPolyPid Ltd
Fecha de salida a bolsaJun 26, 2020
Director ejecutivoMs. Dikla Czaczkes Akselbrad
Número de empleados57
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 26
Dirección18 Hasivim Street, P.O Box 7126
CiudadPETAH TIKVA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal4917002
Teléfono972747195700
Sitio Webhttps://www.polypid.com
Símbolo de cotizaciónPYPD
Fecha de salida a bolsaJun 26, 2020
Director ejecutivoMs. Dikla Czaczkes Akselbrad
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Accionistas
Accionistas
Proporción
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
19.88%
Hedge Fund
19.57%
Holding Company
10.87%
Individual Investor
9.02%
Corporation
5.77%
Investment Advisor/Hedge Fund
4.75%
Private Equity
4.54%
Investment Advisor
0.28%
Research Firm
0.02%
Other
25.31%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
41
7.61M
74.69%
+1.40M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
2023Q3
57
479.04K
37.01%
+97.48K
2023Q2
57
472.86K
36.65%
+91.51K
2023Q1
59
332.36K
28.62%
+89.40K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Aurum Ventures M.K.I.
2.03M
19.88%
+11.34K
+0.56%
Feb 26, 2025
Centaurus Investments Limited
1.11M
10.87%
+475.10K
+75.12%
Dec 31, 2024
Rosalind Advisors, Inc.
1.02M
9.99%
--
--
Mar 31, 2025
Nir (Yehuda)
613.91K
6.02%
+62.60K
+11.36%
Mar 31, 2025
Hewlett Fund, L.P.
587.92K
5.77%
+338.44K
+135.66%
Feb 26, 2025
Triple Gate Capital, LP
465.84K
4.57%
+465.84K
--
Feb 26, 2025
AIGH Capital Management, LLC.
510.95K
5.01%
-507.07K
-49.81%
Mar 31, 2025
Worth Venture Partners, LLC
429.43K
4.21%
+153.81K
+55.80%
Mar 31, 2025
Lukach (Aharon)
299.55K
2.94%
-5.64K
-1.85%
Mar 31, 2025
Dafna Capital Management, LLC
291.27K
2.86%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Fecha
Tipo
Relación
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
